Livongo has closed a new round of investment and will use funds to accelerate growth, add new chronic conditions, and speed international expansion.
Out are the bubonic plague and the Spanish influenza. In are chronic conditions such as diabetes, high blood pressure, and depression. These are the new epidemic.
Dr. Jennifer Schneider shares her personal and professional experience in using big data to care for each person, an n of 1.
Glen Tullman shares his point of view on CIO Review in an articled entitled, “The 3 Ways Software is About to Eat Healthcare.”
FierceBiotech Features Livongo and Voluntis Partnership
“Livongo Health has struck a deal to offer Voluntis’ insulin dose recommendation medical device as part of its diabetes management service. The partners hope to improve treatment adherence and dose optimization by delivering automated recommendations to Livongo members’ smartphones.
Voluntis is contributing its FDA-cleared app, Insulia, to the alliance. The service enables clinicians to set up personalized treatment plans for their patients. Clinicians base the plan on their patient’s profile, insulin prescription and blood glucose targets. Based on this information and blood sugar readings, Insulia provides insulin dose recommendations and coaching messages to users, either via an iOS or Android app or a web portal.”